U.S. Markets closed

A Huge Decision Is on Tap for This Little Biotech Stock

Todd Campbell, The Motley Fool

Investors have their doubts about Geron Corp. 's (NASDAQ: GERN) lead drug candidate, imetelstat, but that didn't keep the company's shares from soaring earlier this year following news that Johnson & Johnson (NYSE: JNJ) will decide whether to continue co-developing imetelstat soon. A decision from J&J is expected before the end of the Q3 2018, and regardless of what the Goliath biopharma decides to do, it could have massive implications for investors. Should you be buying Geron Corp.'s stock now?

A bit of background

Johnson & Johnson is teamed up with Geron Corp. on imetelstat's use in hematologic myeloid malignancies, including myelofibrosis, a life-threatening disease affecting tens of thousands of patients in the U.S. alone.

A man in a suit biting his fingernail.

IMAGE SOURCE: GETTY IMAGES.

J&J paid Geron Corp. $35 million upfront and it committed to equally share in imetelstat's development costs when it licensed it; however, J&J's license includes an option to walk away from imetelstat if it's unhappy with the drug's performance in phase 2 trials.

An approval in myelofibrosis could generate hundreds of millions in sales for the companies because there's a big unmet need for new treatment alternatives; however, early-stage imetelstat trial results have called into question its efficacy.

J&J previously ditched a low-dose arm of imetelstat in one study after an interim look at data disappointed. Furthermore, data reported so far on imetelstat suggests it may not reduce spleen volume by as much as Jakafi, the standard of care currently used in these patients . Because Jakafi's approval was based on a reduction in spleen volume, some investors argue that imetelstat's inability to best it could derail it, unless of course, trials show that imetelstat extends overall survival.

Steps in the right direction

Despite those concerns, J&J hasn't given up on imetelstat yet, and that could suggest that the data it's seen so far is good enough for it to continue working with Geron Corp. on it.

That thinking was supported by news earlier this year that after reviewing study data in March, J&J decided to enroll an extension study that will allow long-term treatment and follow-up of imetelstat patients.

Investors were also encouraged by imetelstat data earlier this year from an ongoing trial in patients with low- to intermediate-risk myelodysplastic syndromes who've failed to respond to prior treatment with an erythropoiesis-stimulating agent.

Specifically, that data showed that 54% of patients achieved blood transfusion independence lasting at least 8 weeks, and 31% achieved 24 weeks of transfusion independence. Last August, J&J decided to enroll 20 more patients who haven't been treated with Revlimid or a hypomethylating agent (HMA) and who don't have a deletion 5q chromosomal abnormality in this study, and the 20th patient was enrolled in that study cohort in February. It's certainly possible that J&J's willingness to expand the study shows it hopes that, at a minimum, it can develop imetelstat for us in at least some patients.

Optimism has also been boosted recently by J&J's decision to include listing imetelstat in its investor presentations as a top drug in its pipeline, a move the company might not have made if it was leaning against going forward with Geron Corp. on this drug.

What's at stake

If J&J continues working with it on imetelstat, then Geron Corp. can exercise co-development and commercialization rights that allow it to make more money on the drug if it's ever approved by regulators.

If Geron Corp. exercises these rights, it will be on the hook for 20% of any additional development costs, but it will receive a $65 million milestone payment, plus up to $820 million in development, regulatory, and sales-based milestones. Additionally, it can collect royalties on any eventual sales that are in the high teens to low 20% range, depending on sales, if imetelstat wins approval.

If Geron Corp. decides against exercising these rights, then it will pocket a $135 million milestone, plus it can receive up to $765 million in development, regulatory, and sales milestones. In this scenario, its royalties on any eventual sales would be in the low double-digit to mid-double-digit percentages.

Alternatively, if J&J decides against continuing to develop imetelstat, then Geron Corp. gets left empty-handed. Yes, it will regain 100% of the rights to imetelstat, but it's unlikely that it would easily find another development partner if J&J balks. If it's forced to go it alone on imetelstat, it would be an expensive proposition that could erase its $103 million in cash pretty quickly.

Impatiently awaiting the news

The binary nature of J&J's decision on Geron Corp.'s future makes Geron Corp. a very risky stock.

Short-sellers have been happy to bet against the company's success, but a surging share price earlier this year did lead to many of them covering their positions. Recently, they've begun shorting the company again, though, which suggests that there's still plenty of pessimism associated with the upcoming decision.

GERN Short Interest Chart

GERN Short Interest data by YCharts .

If short-sellers are proven wrong, and J&J goes forward with imetelstat, it would undeniably be a big catalyst for Geron Corp. Initially, imetelstat would probably get an OK for use in patients that no longer respond to Jakafi, and that's a pretty big market. According to Geron Corp., the 5-year discontinuation rate for Jakafi is 75%. Given that Jakafi sales were $1.54 billion in 2017, I don't think it's a stretch to think that an imetelstat success puts it in a position to capture peak sales in the hundreds of millions annually, or more.

Nevertheless, the uncertainty around J&J's decision makes me think this stock is simply too risky to recommend to anyone. Unquestionably, this is an interesting story worth watching, but I'll be doing it from the sidelines.

More From The Motley Fool

Todd Campbell has no position in any of the stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool owns shares of and recommends Johnson & Johnson. The Motley Fool has the following options: short May 2018 $140 calls on Johnson & Johnson. The Motley Fool has a disclosure policy .

  • Can AMD Stock Go on a Bull Run Once Again?
    Business
    Motley Fool

    Can AMD Stock Go on a Bull Run Once Again?

    Advanced Micro Devices (NASDAQ: AMD) shares have fallen off a cliff over the past month, as investors are probably concerned about whether it can sustain its rally in the face of a fading tailwind and rising competition. The chipmaker has minted a lot of money thanks to cryptocurrency mining, but that catalyst is fizzling out and rival NVIDIA (NASDAQ: NVDA) has launched a new generation of graphics chips to reclaim its lost market share. AMD blames weak GPU sales to the cryptocurrency market for this slowdown, but recent developments indicate that it could easily surpass the low-balled guidance.

  • Better Buy: Aurora Cannabis Inc. vs. Canopy Growth Corporation
    Business
    Motley Fool

    Better Buy: Aurora Cannabis Inc. vs. Canopy Growth Corporation

    Canadian marijuana producers have entered a new era. After several years of supplying medical marijuana nationwide, they have begun moving into Canada's recreational marijuana market, which opened on Oct. 17. Canopy's share price has soared three times higher than Aurora's has.

  • 3 Warren Buffett Stocks Worth Buying Now
    Business
    Motley Fool

    3 Warren Buffett Stocks Worth Buying Now

    Known as the Oracle of Omaha, Warren Buffett has collected both an incredible investment record and a deservedly vast following among investors of all types. Every move he makes is scrutinized in the hope of gleaning  wisdom from his investment choices.

  • 3 Dividend Stocks That Pay You More Than Coca-Cola Does
    Business
    Motley Fool

    3 Dividend Stocks That Pay You More Than Coca-Cola Does

    With a better than 50-year history of paying dividends, Coca-Cola (NYSE: KO) is seen as an icon of stable, strong, secure payouts. Although Coke and its dividend are not in trouble, there are better investments to be found. Three stocks that these Motley Fool contributors particularly like are Dominion Energy (NYSE: D), AbbVie (NYSE: ABBV), and MGM Growth Properties (NYSE: MGP).

  • Kamala Harris proposes new tax credit
    Politics
    Fox Business Videos

    Kamala Harris proposes new tax credit

    “Bulls & Bears” panel discusses how Sen. Kamala Harris (D-Calif.) is proposing a new tax credit, which would provide families making less than $100,000 a year with an extra $500 a month.

  • Better Buy: Ford Motor Company vs. General Motors
    Business
    Motley Fool

    Better Buy: Ford Motor Company vs. General Motors

    Both Ford Motor Company (NYSE: F) and General Motors (NYSE: GM) have been investor favorites in the not-too-distant past, and both pay good dividends. Ford has a slew of new products on the way, starting with a brand-new Ranger pickup early next year. Ford and GM have both had a rough year in the stock market.

  • Which Canadian Marijuana Stock Will Enjoy a Bigger Bump From Its NYSE Listing -- Aphria or Aurora?
    Business
    Motley Fool

    Which Canadian Marijuana Stock Will Enjoy a Bigger Bump From Its NYSE Listing -- Aphria or Aurora?

    Maybe Wall Street should be called "Weed Street." Big Canadian marijuana grower Canopy Growth listed its stock on the New York Stock Exchange (NYSE) earlier this year. Aurora Cannabis (NASDAQOTH: ACBFF) begins trading on the NYSE on Tuesday, Oct. 23. Aphria (NASDAQOTH: APHQF) filed last week to list its stock on the NYSE.

  • Hate Taxes? 37 States Make Social Security Tax Free
    Business
    Motley Fool

    Hate Taxes? 37 States Make Social Security Tax Free

    Over the course of your career, you'll probably have tens of thousands of dollars in Social Security payroll taxes withheld from your paychecks. Workers are confident that by paying those taxes up front, they'll be able to collect Social Security benefits

  • How the Heck Did Netflix Stock Go Down Last Week?
    Business
    Motley Fool

    How the Heck Did Netflix Stock Go Down Last Week?

    Everything seemed to go right for Netflix (NASDAQ: NFLX) last week. It has another hit on its hands with The Haunting of Hill House, an eight-part horror series based on Shirley Jackson's novel that has even won the praise of the immortal Stephen King. Netflix is killing it, but investors are unfortunately singing a different tune.

  • With crude around $70, it’s time to sell your oil stocks
    News
    MarketWatch

    With crude around $70, it’s time to sell your oil stocks

    The energy sector has been whipsawed by headlines lately, and many investors can’t decide whether to buy or sell oil stocks. When oil (CLX8) raced up to a new 52-week high of more than $76 to start October, many thought things looked great. Then as U.S. oil supplies rose and as OPEC production rose, things didn’t look so hot.

  • Suze Orman has a killer question for your retirement
    Business
    MarketWatch

    Suze Orman has a killer question for your retirement

    Suze Orman is one of those singular personalities in the financial business who seems to be right on the pulse of everyone she meets. She’s written books, starred in her own television show and made innumerable appearances in person. Like Oprah

  • The ‘smart money’ says it’s time to buy the Chinese internet giants and the U.S. FAANGs
    News
    MarketWatch

    The ‘smart money’ says it’s time to buy the Chinese internet giants and the U.S. FAANGs

    When the media and investors turn negative on stocks but the “smart money” is bullish, it’s a good time to think about buying. After all, exactly what is the smart money, and how do you know? Lately, several fund managers who pass this test have been pounding the table on Chinese internet names.

  • Business
    Benzinga

    Morgan Stanley's Recipe For Strong Q4 Guidance From Tesla

    Tesla Inc. (NASDAQ: TSLA) is set to report third-quarter earnings data in early November after a whirlwind of a quarter that included a chain of events that began Aug. 7 with CEO Elon Musk’s “funding secured” tweet and ended with a Securities and Exchange

  • This Warren Buffett Stock Is Dirt Cheap Right Now
    Business
    Motley Fool

    This Warren Buffett Stock Is Dirt Cheap Right Now

    Warren Buffett has amassed a large portfolio of bank stocks for Berkshire Hathaway (NYSE: BRK-A) (NYSE: BRK-B) with major holdings in Bank of America (NYSE: BAC), Wells Fargo (NYSE: WFC), and American Express (NYSE: AXP), just to name a few of the most well-known and largest investments. Synchrony is a major issuer of store-branded credit cards and also operates a rapidly growing online banking platform.

  • 3 Stocks to Supplement Your Social Security Income
    Business
    Motley Fool

    3 Stocks to Supplement Your Social Security Income

    Social Security isn't meant to replace your entire paycheck. Enterprise Products Partners L.P. (NYSE: EPD), Duke Energy Corporation (NYSE: DUK), and W.P. Carey Inc. (NYSE: WPC) are three great options to consider. Enterprise Products Partners is one of the largest midstream energy companies in North America, offering a generous distribution yield of roughly 6%.

  • Should Congress cut entitlement programs to combat rising deficit?
    Politics
    Fox Business Videos

    Should Congress cut entitlement programs to combat rising deficit?

    Maya MacGuineas, Committee for a Responsible Federal Budget, and Wall Street Journal editorial page deputy editor James Freeman discuss America’s deficit problem and how President Trump asked members of his Cabinet to cut their departments’ budgets by 5 percent.

  • Why Valero Energy, eBay, and New Age Beverages Slumped Today
    Business
    Motley Fool

    Why Valero Energy, eBay, and New Age Beverages Slumped Today

    Some major market benchmarks managed to hang onto their gains, but the Nasdaq Composite, and Russell 2000 indexes posted losses of 0.5% to 1.25%, and the S&P 500 was virtually flat. Valero Energy (NYSE: VLO), eBay (NASDAQ: EBAY), and New Age Beverages (NASDAQ: NBEV) were among the worst performers on the day. Valero Energy dropped 10% after the refinery company announced that it would buy back all outstanding units of its related MLP, Valero Energy Partners (NYSE: VLP).

  • 3 Top Stocks Under $5
    Business
    Motley Fool

    3 Top Stocks Under $5

    If you're looking for cheap stocks, focusing too much on share price is a mistake. Companies like Zynga (NASDAQ: ZNGA), Chesapeake Energy (NYSE: CHK), and Ascena Retail Group (NASDAQ: ASNA) have mounted impressive comebacks over the past year, and the future could hold even further gains if the industry conditions that they face take a turn for the better.

  • 3 Great Stocks Under $10
    Business
    Motley Fool

    3 Great Stocks Under $10

    Among the stocks you can currently purchase for less than $10 per share are Sirius XM Holdings (NASDAQ: SIRI), Annaly Capital Management (NYSE: NLY), and Infosys (NYSE: INFY), and below, we'll take a look at how long they're likely to remain this cheap for would-be investors. Sirius XM was a pioneer in the satellite radio industry, and it's been an investor favorite for years.

  • Here's Which Marijuana Stocks Investors Are Betting Against the Most
    Business
    Motley Fool

    Here's Which Marijuana Stocks Investors Are Betting Against the Most

    Canada's recreational marijuana market is now open for business. Some are confident enough that certain marijuana stocks will fall that they're putting a lot of money on the line expecting that's exactly what will happen. The marijuana grower's low stock float and wild swings over the last month have received a lot of attention.

  • 3 Energy Stocks You Can Buy and Hold for the Next Decade
    Business
    Motley Fool

    3 Energy Stocks You Can Buy and Hold for the Next Decade

    North America needs to build $23 billion of new natural gas-related infrastructure annually through 2035, according to a recent report. Three of the best positioned to capture this growth are Kinder Morgan (NYSE: KMI), Williams Companies (NYSE: WMB), and TransCanada (NYSE: TRP), making them great stocks to buy and hold in the coming decade. Kinder Morgan is already the largest natural gas pipeline company in North America, operating roughly 70,000 miles of pipeline.

  • This Midstream Oil & Gas Stock Is Still a Steal
    Business
    Motley Fool

    This Midstream Oil & Gas Stock Is Still a Steal

    The midstream sector is out of favor today, with the Alerian MLP ETF still off roughly 45% from its mid-2014 highs. Midstream companies own the assets that move oil, natural gas, and related products around the country. Investors were pretty excited about this space a few years back, pushing the prices of midstream companies higher and their yields lower.

  • Is Enbridge Inc. a Buy?
    Business
    Motley Fool

    Is Enbridge Inc. a Buy?

    With a roughly $55 billion market cap, Canada-based Enbridge Inc. (NYSE: ENB) is among the largest energy companies in North America. It offers investors a robust 5.5% yield and has increased its dividend annually for 22 consecutive years. Enbridge is generally considered a well-run company, the proof of which is in its impressive dividend history.

  • Procter & Gamble Finally Has Some Good News for Investors
    Business
    Motley Fool

    Procter & Gamble Finally Has Some Good News for Investors

    It has taken some time, but Procter & Gamble (NYSE: PG) shareholders are finally seeing improving results out of the consumer products titan. P&G paired that positive revenue news with an uptick in profitability, too. P&G's expansion rate sped up significantly, with help from strong sales volumes and steady pricing.

  • Why Advanced Micro Devices, Inc. Stock Closed 11% Lower on Friday
    Business
    Motley Fool

    Why Advanced Micro Devices, Inc. Stock Closed 11% Lower on Friday

    Analyst Pierre Ferragu from financial firm New Street Research set his price target for AMD at $18 per share, arguing that the stock has been priced for a level of success that simply isn't realistic. "AMD's stock price reflects a scenario we don't believe possible," Ferragu wrote. In particular, Ferragu sees larger rival Intel (NASDAQ: INTC) getting its manufacturing act together as we speak.